

# Use of dsRNA WSSV VP19 with Different Dose for Infection Control White Spot Syndrome Virus (WSSV) in Vanname Shrimp.pdf

*by*

---

**Submission date:** 24-Jun-2023 10:56AM (UTC+0700)

**Submission ID:** 2121719735

**File name:** Use of dsRNA WSSV VP19 with Different Dose for Infection Control White Spot Syndrome Virus (WSSV) in Vanname Shrimp.pdf (334.82K)

**Word count:** 5046

**Character count:** 25378

# USE OF dsRNA WSSV VP19 WITH DIFFERENT DOSE FOR INFECTION CONTROL White Spote Syndrome Virus (WSSV) IN VANAME SHRIMP *Litopenaeus vannamei*

Binayanti<sup>1)</sup>, Hilal Anshary<sup>2)</sup>, Andi Parenrengi<sup>3)</sup>, A. Citra Malina<sup>4)</sup>

<sup>1)</sup> Master Program of Fisheries Science, Hasanuddin University  
<sup>2)</sup> Marine Science and Fisheries Faculty of Hasanuddin University  
Makassar – South Sulawesi

DOI: 10.29322/IJSRP.9.08.2019.p9230

<http://dx.doi.org/10.29322/IJSRP.9.08.2019.p9230>

**Abstract-** Increased production of *litopenaeus vannamei* vannamei shrimp continues to be pursued, one of which is by increasing shrimp immune response to infection with WSSV disease. This study aims to evaluate the best dosage of dsRNA VP19 WSSV *in-vitro* production to increase the immune response of vannamei shrimp (*L. vannamei*). The isolation of the VP19 gene and the construction of the VP19 vaccines were carried out using the Megascript kit with VP 19 genomic DNA as a template. Vaccination was carried out by injection method on vannamei shrimp with an average weight of  $10.5 \pm 3.5$  g and a length of  $11.05 \pm 1.95$  cm. The vaccine dose tested was 0.02  $\mu$ g, 0.2  $\mu$ g, 2  $\mu$ g; and as controls are shrimp that are not vaccinated. The study consisted of four vaccine dose treatments with each of two replication and maintenance for five days. The challenge test was carried out for five days by injecting the WSSV virus in saline solution (1 v/v). The differential hemocyte count (DHC) calculation was carried out before the challenge test and after the challenge test on days 1, 2, and 3. Data analysis was performed statistically by analysis of variance (ANOVA). VP19 gene isolation, construction with T7 promoter, and making of WSSV VP19 dsRNA were successfully carried out, and application of dsRNA vaccine in vannamei shrimp with a dose of dsRNA vaccine of 2.0  $\mu$ g had a significant effect ( $P < 0.05$ ) on granular hemocytes cells

**Index Terms-** VP19 dsRNA, differential hemocyte count (DHC), vannamei shrimp, dose.

## I. INTRODUCTION

Shrimp is one of the fisheries commodities which have high economic value and are widely cultivated in Indonesia, especially vannamei shrimp (*Litopenaeus vannamei*) and Black tiger *Penaeus monodon* (Tassanakajon et al., 2013). Vannamei *L. vannamei* shrimp is widely cultivated today, because it is known to have superior resistance to virus attacks and environmental changes compared to tiger shrimp. But the current reality of vannamei shrimp cultivation also often fails due to virus attacks

(Subyakto et al., 2009). One common virus that infects shrimp is white spot syndrome virus (WSSV). During the last 20 years, WSSV has been considered a viral pathogen that has the most negative impact on the shrimp culture industry. This is due to its high virulence, rapid spread, occurring in all shrimp producing countries, a mass mortality which can reach up to 100% within 3 to 7 days after the first clinical signs seem, reducing production with a large economic loss (Lucero et al., 2016).

Prevention and treatment of viral infections is very challenging because the virus uses stem cell structures to replicate, inhibiting viral replication without damaging the structure of the host cell. Researchers have recently begun to use RNA interference (RNAi) technology to selectively inhibit viral genes that are important for virulence (Shuey et al., 2002). The RNAi technology has the role of inhibiting post-gene transcription through formation of dsRNA segments in the mRNA transcript, resulting in proper mRNA degradation. Vaccination technology uses viral dsRNA agents to develop very rapidly, especially in the fields of medical, agricultural, and aquaculture (Lichner et al., 2003; Rowley & Pope, 2012). In the field of aquaculture, this technology developed to overcome diseases caused by viruses in shrimp (Mejía-Ruiz et al., 2011; Ahanger et al., 2014). Some shrimp vaccination studies using WSSV agents as vaccine sources have shown progress and obtained encouraging results (Huang et al., 2014; Kumar et al., 2015; Puneeth et al., 2017).

WSSV is a double-stranded DNA (dsDNA) virus formed from complex macromolecules that are specifically attached and arranged for the protection and transfer of viral genomes. WSSV genes transcribed in the late phase include genes that encode WSSV main structural proteins, namely VP28, VP26, VP24, VP19, and VP-15. Where, this viral protein is likely to be used as a recombinant vaccine (Sánchez-Paz, 2010). VP19 is a WSSV wrap protein that is important because of its involvement in systemic infections in shrimp (Nadala et al., 1998; van Hulten, 2001b; Zhang et al., 2002). The latest results of the study were reported by Nurhaeda (2017), who succeeded in making VP19 dsRNA vaccine which was able to increase the survival, immune response and histology of vannamei shrimp.

Isolation and characterization of the WSSV VP19 virulent gene has been successfully carried out (Nurhaeda, 2017), but as a dsRNA vaccine in increasing survival, immune response and histology of shrimp with various doses after challenge tests WSSV is still lacking, so this study needs developed with using various doses as an effort to control WSSV infection in vannamei shrimp. This study aims to evaluate the best dose of WSSV VP19 DNARNA *in-vitro* production to increase the immune response of vannamei shrimp (*L. vannamei*).

## II. MATERIALS AND METHODS

### 2.1 Research Materials

The shrimp genome material that was use was the vannamei that was positively infected with the WSSV virus. The genomic DNA collection from the Laboratory of Brackish Water Biotechnology Research Center for Brackish Water Aquaculture and Maros Fisheries Extension (BRPBAP3) in Maros.

### 2.2 Research Methods

Stages carried out in the research to produce VP19 dsRNA are: Isolation of VP19 gene, Construction of VP19 WSSV gene with *in-vitro* RNAi method, and production of WSSV VP19 dsRNA, then application to test animals to see Differential Haemocyte Count (DHC) after challenge test.

#### a. Isolation of WSSV VP19 Encoding Genes

Isolation of the VP19 gene carried out using the PCR technique. The DNA genome that has been isolated from vannamei shrimp used as a template for DNA (template) in the PCR process, using the forward primer VP19 F 5'-CGC GAT CAC CAC GAC TAA CAC-3 and reverse VP19 R 5'-CCG primer GAA TTC TTA CTG CCT CCT CTT GGG-3 with a target of 366 bp (Sarathi *et al.*, 2010).

Amplification performed on the System 2700 PCR GeneAmp PCR engine (Applied Biosystem). The PCR reaction is the PureTaq Ready-To-Go PCR Beads-GE Healthcare (2.5 units of PuReTaq DNA polymerase; 200  $\mu$ M each dNTP; 10 mM Tris-HCl pH 9 at room temperature; 50 mM KCl; 1.5 mM MgCl<sub>2</sub>) and primer 1  $\mu$ L each, 0.5  $\mu$ L vannamei shrimp DNA genome, and nuclease free water 22.3  $\mu$ L with a last volume of 25  $\mu$ L.

Then sample the spin down for  $\pm$  10-15 seconds. Samples entered into PCR machines PCR amplification reactions as follows: pre-denaturation 94°C for 5 minutes in 1 cycle; 35 cycles for denaturation of 94°C for 30 seconds, annealing 53°C for 30 seconds, extension 72°C for 30 seconds; and the last 72°C extension for 7 minutes then added 4°C at the end of the cycle.

Next to see the success of amplification of target DNA fragments, 1  $\mu$ L sample was electrophoresis on 1% agarose gel with 20 mL TAE 1 buffer solvent, then 1  $\mu$ L gel added documented with Gel Documentation System. The molecular weight of the DNA fragment determined using a 100 bp plus marker.

#### b. WSSV VP19 Gen Construction with T7 Promoter

Construction of WSSV VP19 gene with T7 promoter carried out by PCR technique. T7 VP19 WSSV gene is used as a template using the T7 VP19 primer: 5'-TAA TAC

GAC TCA CTA GAC GGA GCG GAT CCATG GCC ACC CTA ACC-3 CTA 'and T7 VP19R primer: 5'-TAA TAC GAC TCA CTA TAG GGA CGG AAT TCT TAC TGC CTC CTC TTG GGG-3'(bottom line is T7 primary sequence).

Amplification performed on the System 2700 PCR GeneAmp PCR engine (Applied Biosystem). The PCR reaction used was the PureTaq Ready-To-Go PCR Beads-GE Healthcare kit by adding primers of 2.5  $\mu$ L, 0.5  $\mu$ L of the mold genome, and nuclease-free water 19.5  $\mu$ L with a final volume of 25  $\mu$ L.

Samples were inserted into the PCR machine with PCR conditions as follows: 94°C for 5 minutes, followed by 25 cycles of 94°C for 30 seconds, annealing temperature of 72°C for 30 seconds and extension 72°C for 30 seconds, followed by last extension of 72°C for 7 minutes.

Next to see the success of amplification of target DNA fragments, 1  $\mu$ L sample was electrophoresed on 1% agarose gel with 20 ml TAE 1 buffer solvent, then added 1  $\mu$ L of gel documented with Gel Documentation System. The molecular weight of the DNA fragment determined using a 100 bp plus marker.

Nexted PCR with the premier T7 VP19, on the PC 27 GeneAmp PCR (Applied Biosystem) PCR engine. The PCR reaction used was the PureTaq Ready-To-Go PCR Beads-GE Healthcare kit by adding primers of 2.5  $\mu$ L each, 0.5  $\mu$ L of the mold genome and nuclease-free water 19.5  $\mu$ L with a final volume of 25 mL.

Samples were inserted into the PCR machine with PCR conditions as follows: 94°C for 5 minutes, followed by 25 cycles of 94°C for 30 seconds, annealing temperature of 72°C for 30 seconds and extension 72°C for 30 seconds, followed by last extension of 72°C for 7 minutes.

Next to see the success of amplification of target DNA fragments, 1  $\mu$ L sample was electrophoresis on 1% agarose gel with 20 ml TAE 1 buffer solvent, then added 1  $\mu$ L of gel documented with Gel Documentation System. The molecular weight of the DNA fragment determined using a 100 bp plus marker.

#### c. Manufactures WSSV dsRNA-VP19

The PCR results used for the synthesis of dsRNA using the MEGAscript RNAi (Ambion) kit. The sample used to produce dsRNA is a sample that was successfully constructed with the T7 promoter.

The concentration of PCR products measured to find the number of PCR products to be used in making the RNase H dependent reaction. Subsequently added to the new tube: Adenine triphosphate (ATP), Cystidine triphosphate (CTP), Guanosine triphosphate (GTP), Uridine triphosphate (UTP) (2  $\mu$ L); T7 Buffer (2  $\mu$ L); T7 enzyme mix (2  $\mu$ L); PCR products (1.5  $\mu$ L); Nuclease-free water 6.5  $\mu$ L; Total tube 1 (20  $\mu$ L) Appendix 1.

Then in the spin down at medium speed and incubated at the incubator at 37°C for 6 hours (every 30 minutes the sample shaken). For the Annealing process, it was re-incubated at 75°C for 5 minutes then cooled to room temperature for about 3 hours then the dsRNA stored at -20°C and -80°C until it reused. Then the process of Digestion DNA and ssRNA uses MEGAscript RNAi kit (Ambion) with the following composition: dsRNA VP19 (tube 1) 20  $\mu$ L; Nuclease-free water (21  $\mu$ L); Digestion buffer (5  $\mu$ L); DNase I (2  $\mu$ L); RNase A (2  $\mu$ L) Total tube 1 (50  $\mu$ L).

After all the ingredients mixed then spindown and incubated at 37°C for 1 hour (not more than 2 hours). Then leave it at room temperature for 5 minutes. The next process is purification which aims to remove proteins, free nucleotides, and nucleic acid degradation products from dsRNA, namely dsRNA (tube 1) (50 µL); 10x binding buffer 50 µL; Nuclease-free water (150 µL); 100x ethanol (250µL); Total tube 1 (500 µL).

These ingredients added to tube 1 and spin down, after which then added to the filter cartridge. Then centrifuge at a speed of 14,000 rpm at 4°C for 2 minutes. The supernatant is remove, add 500 µL wash solution and centrifuge at a speed of 14,000 rpm at 4°C for 2 minutes. The supernatant is discard, add 500 µL wash solution and centrifuge with a speed of 14,000 rpm at 4°C for 2 minutes. The supernatant removed and repeat the dry centrifuge, homogenized it with 50 µL elution solution (95°C), centrifuge at a speed of 14,000 rpm at 4°C for 2 minutes. homogenized again with 50 µL elution solution (95°C), centrifuge at 14,000 rpm at 4°C for 2 minutes. Homogenate is remove and the supernatant is remove. Furthermore, measuring WSSV VP 19 dsRNA concentration and to see the success of the target RNA in electrophoresis by using agarose 1% with TAE 1x buffer solvents as much as 20 mL and added as much as 1 µL and documented with Gel Documentation System (Appendix 2). The molecular weight of the DNA fragment determined using a 100 bp plus marker.

#### d. Application of WSSV dsRNA-VP19 to Vannamei Shrimp

Experiments conducted to test whether dsRNA VP19 with different doses can improve the survival and immune response of vannamei shrimp against WSSV virus infection and to see the level of hepatopancreas tissue damage in test animals. The limits to observed are DHC.

The study will be designed using a Completely Randomized Design (CRD) with 4 treatments and each treatment each has 3 replications. Thus this study consisted of 12 experimental units. The vaccine dose tested refers to the study of Loy et al. (2012) namely a. Shrimp injected with saline solution (SS) without vaccine (control), 0.02 µg, 0.2 µg and 2.0 µg

#### 1. experiment animals

The vannamei shrimp used came from Barru Regency ponds with an average weight of 10.5 ± 3.5 g and an average length of 11.05 ± 1.95 cm. The shrimp have been vaccinated maintained in a fiber-controlled tub measuring 80 cm x 80 cm x 60 cm which equipped with aeration, with density of 10 fish / tub, using sea water media and fed with commercial feed 2% of body weight and

given 2 times a day before the challenge test and 4 times a day after the challenge test.

#### 2. dsRNA vaccine

On the first day, the shrimp in each treatment injected with VP19 dsRNA with the dose tested in the second segment of the abdominal section using a syringe volume of 1 mL and 0.1 mL in each test shrimp. The test animals were then maintained until the third day, then tested challenged with the WSSV virus.

#### 3. Test challenges using the WSSV virus

The challenge test was to infect the WSSV virus through the injection method into vannamei shrimp. WSSV isolates came from the Maros BRPBAP3 Fish and Environmental Health Laboratory which been tested molecular. On the 3rd day after vaccination, challenge tests carried out by injecting 0.1 mL WSSV virus in each test shrimp. Before the challenge test carried out, first take a hemolymph sample from each treatment randomly (4 individuals per treatment group) to observe the immune response. During the study, observation carried out.

#### 4. Differential Haemocyte Count (DHC)

Differential hemocytes are then calculated by grouping hemocytes into 3 cell types (granular, semi granular, and hyaline), the percentage of each cell type calculated using the formula:

$$\text{DHC (\%)} = \frac{\text{number of each type of hemocyte cell}}{\text{hemocyte count}} \times 100\%$$

#### 2.3 Data Analysis


The parameters of the DHC immune response were analyzed using the ANOVA test at the level of 0.05.

### III. RESULTS AND DISCUSSION

#### 1. Characteristics of the WSSV VP19 gene

##### a. Isolation of WSSV VP19 encoding gene

The VP19 encoding gene was successfully isolated from WSSV on the vannamei shrimp genome DNA which was positively infected with white spot disease using the PCR technique using VP19F and VP19R specific primer. Electrophoresis results showed that one DNA fragment at position of around 366 bp (Figure 1a) and VP19 gene construction was also successfully carried out on the nexted promoter T7 (T7 VP19). Can be seen in (Figure 1b) which shows an increase in DNA fragments from VP19 position between 400-500bp.




**Gambar 1.** Electrophoresis results of PCS VP19 WSSV (a) and nexted PCR T7 VP19 WSSV (b) isolated from the vannamei shrimp genome that were positively infected by WSSV. M = marker 100+, VP19 = gene VP19, NT7 = nexted T7 PCR, T7VP19 = promoter T7 VP19, (-) = negative control.

The results of PCR amplification and authentication with VP19 WSSV encoding gene electrophoresis, DNA fragment bands at position of around 366 bp which showed that the VP19 encoding gene was successfully isolated from the vannamei shrimp genome that was positively infected with the WSSV virus. This has also been successfully carried out in isolating other VP19 and VP-WSSV encoding genes in both vannamei shrimp and tiger shrimp. The results of the study carried out by Alim *et al.* (2011), reported that isolation of the WSSV VP19 gene encoding in tiger shrimp Situbondo isolates was 366 bp; Tenriu *et al.* (2015), showed that the VP24 WSSV encoding gene was successfully isolated from tiger shrimp with a sequence length of about 621-648 bp; Parenrengi *et al.* (2017), reported that VP15 was successfully isolated from tiger shrimp with ORF DNA fragment length (open reading frame) of 243 bp; Hidayani *et al.* (2016), showed the success of isolating the coding gene for WSSV VP19 protein in vannamei juvenile of Indonesian isolates with a DNA fragment length of 387 bp; Hidayani *et al.* (2013), reported that gene encoding of the VP19 WSSV protein in tiger shrimp had a size of 386 bp; Malina *et al.* (2013), reported that isolation of VP28 surface protein encoding genes from tiger shrimp was successfully carried out with a fragment length of 672 bp. The results of the VP-WSSV encoding genes isolated from the shrimp genome infected with WSSV showed that the primary pair was specifically able to amplify the VP-WSSV gene from the shrimp genome infected with WSSV. Furthermore, it said that differences in genome size show chance of mutations caused either by deletion or presence of certain sizes of insertion in the WSSV genome (Yang *et al.*, 2001).

#### b. Production of WSSV dsRNA-VP19 *in-vitro*

Production of WSSV VP19 dsRNA was successfully carried out *in-vitro* using the MEGAscript RNAi kit with purity of 1.96 and a concentration 850 µg / mL, where a purity level above 1.8 was indicated as a product for production of dsRNA. Linacero *et al.* (1998), recommend the ratio value for pure double-stranded DNA between 1.8–2.0. The same method carried out for production of *in-vitro* gonad inhibiting hormone (GIH) dsRNA using the MEGAscript RNAi kit (Wulandari, 2010). The success of *in-vitro* dsRNA production using the MEGAscript kit is characteristic by high levels of purity, and an increase in fragments or parallel to the control fragments, and the WSSV


VP19 dsRNA fragment band seen as verified by 1% agarose electrophoresis. This result can be seen in (Figure 2) there is a VP19 DNA fragment that constructed with the T7 promoter.




**Gambar 2.** Electrophoresis produced by WSSV dsRNA-VP19. M = marker100 +, VP19 = VP19 gene, NT7 = nexted promoter T7, dsRNA = WSSV dsRNA-VP19 production.


## 2. Differential Haemocyte Count (DHC) 33

Based on the results of the study before and after the challenge test with the WSSV virus at each dose showed an average DHC value, the number of hyaline hemocytes cells dose 0 µg, 0.02 µg, 0.2 µg, and 2 µg before the challenge test which is 69%, 76 %, 74% and 72%. After that, semi granular 26%, 17%, 20%, and 22%. Furthermore, granular is 5%, 7%, 7% and 6%. The results after the challenge test were obtained for the average DHC values of hyaline, semi granular, and granular hemocytes with doses of 0 µg, 0.02 µg, 0.2 µg, and 2 µg on days 1, 3 and 5th is hyaline (52%, 77%, 64%, and 68%), (78%, 11%, 64%, and 68%), (69%, 76%, 69%, and 69%), Variety analysis showed no significant difference ( $P > 0.05$ ) in each treatment. Semigranular (35%, 21%, 27% and 25%), (18%, 30%, 24%, and 20%), (7%, 19%, 20%, and 17%), variance analysis showed no significant influence ( $P > 0.05$ ) on each treatment. Granular (13%, 1%, 9%, and 7%), (4%, 6%, 13% and 12%), (4%, 5%, 11% and 14%) the results of the tukey advanced test show differences that real ( $P < 0.05$ ) in each treatment. This result can seen in Figure 3.







Percentage of hemocytes at doses of 0 µg



Percentage of hemocytes at doses of 0.02 µg



Percentage of hemocytes at doses of 0.2 µg



Percentage of hemocytes at doses of 2,0 µg

**Gambar 3.** Percentage of differential haemocyte count (DHC) of vannamei *P. vannamei* imp before and after testing challenged with WSSV virus. ANOVA analysis showed no significant difference ( $P > 0.05$ ) hemocytes cells in each treatment.

The results of the study of hemocyte cell differentiation consisting of hyaline, semigranular, and granular cells of vannamei shrimp before and after the challenge test showed different in the effect that varied in (Figure 3). Hyaline cell results showed no significant difference ( $P > 0.05$ ) in each treatment. Vannamei shrimp hyaline cells were vaccinated and then injected with WSSV decreased on day 1 and day 3, while on day 5 there was an increase compared to controls. Hyaline cells depicted by the absence granular function as cells that do phagocytosis (Smith et al. 2003). Increasing hyaline cells can increase phagocytosis activity against pathogens that enter the crustacean body (Le Moullac et al. 1998; Smith et al. 2003).

Semigranular cells described as having small granules, which function in recognizing and responding to pathogens that enter the crustacean body (Soderhall and Cerenius 1992). While granular cells described as cells that have a large number of granules which function in storing and releasing the proPO system and as toxicity together with semigranular cells (Smith et al. 2003). Although there was a decrease in the percentage of semigranular in this study, granular cells showed a significant effect ( $P < 0.05$ ) which was able to increase phenoloxidase activity which plays a role in the melanization process. Each active cell type in the immune reaction, such as hyaline cells involved in phagocytosis, semigranular cells are active in encapsulation, and granular cells are active in the storage and release of proPO and cytotoxic systems.

#### IV. CONCLUSION

The results showed that VP19 gene isolation, construction with T7 promoter, and making of WSSV VP19 dsRNA were successfully carried out, and the application of dsRNA vaccine in vannamei shrimp with a dose of dsRNA vaccine of 2.0 µg had a significant effect on granular hemocytes

#### V. SUGGESTION

Further research needs to developed on vaccine production in-vivo and evaluates on the day that vaccines increase and survive.

#### REFERENCES

- Ahanger, S., Sandaka, S., Ananad, D., Mani, M.K., Kondadhasula, R., Reddy, C.S., Marappan, M., Valappil, R.K., Majumdar, K.C., & Mishra, R.K. (2014). Protection of shrimp *Penaeus monodon* from WSSV infection using antisense constructs. *Mar. Biotechnol.*, 16, 63-73.
- Alim, S., Wahjuningrum, D., Ali, M. 2011. Pengklonan dan Pengurutan Gen Penyandi Protein Permukaan VP19 WSSV Isolat Situbondo. *Jurnal Akuakultur Indonesia* 10(2):154-164.
- Hidayani, A.A., Malina, A.C. dan Parenrengi, A. 2013. Isolasi dan karakterisasi Gen Penyandi Protein Permukaan VP19 *White Spot Syndrome Virus* (WSSV) pada Udang Windu (*Penaeus monodon* Fabricius, 1798). *Torani, Jurnal Ilmu Kelautan dan Perikanan* No.2 Vol. 23: 58-66
- Hidayani, A.A., Tassakka, A.C.M.A.R., Parenrengi, A. 2016. Isolation and characterization of an envelope protein (VP19) of a *White Spot Syndrome Virus* from diseased vannamei (*Litopenaeus vannamei*) in Indonesia. *AACL Bioflux*, 9(2):389-395.
- Huang, P.Y., Leu, J.H., & Chen, L.L. (2014). A newly identified protein complex that mediates white spot syndrome virus infection via chitin-binding protein. *Journal of General Virology*, 95, 1799-1808.
- Jin, B., Sun, T., Yu, X.H., Liu, C.Q. Yang, Y.X. Lu, P., Fu, S.F., Qiu, H.B., & Yeo, A.E.T. (2010). Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. Review Article. *Journal of Biomedicine and Biotechnology*, p. 1-17.
- Kumar, Anil., Laramore S, Alexander P, F. C. Thomas Allnut, Sayre RT. 2015. Double Stranded RNA Simultaneously Targeting four *White Spot Syndrome Virus* (WSSV) Genes Provides Protection Against WSSV in *Litopenaeus Vannamei*. *Int J Marine Sci Ocean Technol.* 2(2):5-10.
- Le Moullac G, Soyez C, Saulnier D, Ansquer D, Avarre JC and Levy P. 1998. Effect of hypoxic stress on the immune response and the resistance to vibriosis of the shrimp *Penaeus stylirostris* Fish and shellfish immunol. 8:621-629.
- Lichner, Z., Silhavy, D., & Burgya'n, J. (2003). Doublestranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences. *Journal of General Virology*, 84, 975-980.
- Linacero, J., Rueda, Vazquez, A.M. 1998. Quantification of DNA. Pages 18-21, In : Isaac, G., Ingram, D.S., editors. *Molecular Tools for Screening Biodiversity : Plants and Animals*. Chapman and Hall. London, Weinheim, New York, Tokyo, Melbourne, Madras.

- [11] Loy, J.D., Mogler, M.A., Loy, D.S., Janke, B., Kamrud, K., Scura, E.D., Harris, D.L.H., & Bartholomay, L.C. (2012). dsRNA provides sequence-dependent protection against infectious myonecrosis virus in *Litopenaeus vannamei*. *Journal of General Virology*, 93, 880-888.
- [12] Malina, A.C., Hidayani, A.A., Parenrengi, A. 2013. Isolasi dan Karakterisasi Gen Penyandi Protein Permukaan VP28 *White Spot Syndrome Virus* (WSSV) pada Udang Windu (*Penaeus monodon* Fabricus, 1798). Konferensi Akuakultur Indonesia.
- [13] Mejia-Ruiz, C.H., Vega-Peña, S., Alvarez-Ruiz, P., & Escobedo-Bonilla, C.M. (2011). Double-stranded RNA against white spot syndrome virus (WSSV) VP28 or VP26 reduced susceptibility of *Litopenaeus vannamei* to WSSV, and survivors exhibited decreased susceptibility in subsequent re-infections. *Journal of Invertebrate Pathology*, 107, 65-68
- [14] Nadala ECB Jr, Tapay LM, Loh PC. 1998. Characterization of a non-occluded baculovirus-like agent pathogenic to penaeid to penaeid shrimp. *Dis Aquat Organ*. 33: 221–229.
- [15] Nurhaeda, 2017. Penggunaan RNA Untai Ganda (dsRNA) Protein Permukaan 19 (VP19) *White Spot Syndrome Virus* (WSSV) untuk Pengendalian Infeksi Virus WSSV pada Udang Vannamei *Penaeus vannamei*.
- [16] Parenrengi, A., Alimuddin, Tenriulo, A. 2017. Characteristic of a Viral Protein (VP-15) of *White Spot Syndrome Virus* Isolated From Infected Tiger Shrimp *Penaeus monodon*. *Indonesia Aquaculture Journal*, Vol.2 (in press).
- [17] Puneeth, T.G., Akhila, D.S., Dechamma, M.M., Shreeharsha, J.M., Shivakumar, S.K., & Venugopal, M.N. (2017). Comparative efficacy of dsRNA VP24, VP26, RR1 and WSV477 gene against WSSV infection in *Penaeus monodon*. *Int. J. Curr. Microbiol. App.Sci.*, 6(2), 665-674.
- [18] Rowley, A.F., & Pope, E.C. (2012). Vaccines and crustacean aquaculture: A mechanistic exploration. *Aquaculture*, 334-337, 1-11.
- [19] Sánchez-Paz, A. (2010). *White spot syndrome virus*: an overview on an emergent concern. *Vet. Res.*, 41(43), 34.
- [20] Shuey DJ, McCallus DE, Giordano T. RNAi: gene silencing in therapeutic intervention. *Drug Discov Today* 2002;7:1040e6.
- [21] Smith VJ, Janet HB, Hauton C. 2003. Immunostimulation in crustaceans: does it really protect against infection. *Fish and shellfish immunology*. 15:71-90.
- [22] Soderhall K, Cerenius L. 1992. Crustacean immunity. *Annual review of fish disease*, 2:3-23.
- [23] Subyako, S., Sutende D., Afandi M. Dan Sofiati. 2009. Budidaya Udang Vannamei (*Litopenaeus vannamei*) Semiintensif dengan Metode Sirkulasi Tertutup untuk Menghindari Serangan Virus. *Jurnal Ilmiah Perikanan dan Kelautan*, 1(2):121-127.
- [24] Tassanakajon, A., Somboonwivat, K., Supungul, P., & Tang, S. (2013). Discovery of immune molecules and their crucial functions in shrimp immunity. *Fish & Shellfish Immunology*, 34, 954-967.
- [25] Tenriulo, A., Tampangallo, B.R., Parenrengi, A., Dewi, R.A. 2015. Isolasi dan Karakterisasi Gen Penyandi Protein VP-24 WSSV pada Udang Windu (*Penaeus monodon*) untuk Pengembangan Teknologi RNAi. *Prosiding Forum Inovasi Teknologi Akuakultur*.
- [26] Van Hulten, M.C.W., M. Reijus, A. M. G. Vermeesch, F. Zandbergen, and J.M. Valk. 2002. Identification of VP19 and VP15 OF White Spot Syndrome Virus (WSSV) and Glycosylation of The WSSV Major Structural Proteins. *Virology* 35:257-265.
- [27] Wulandari, A.S. 2010. Konstruksi dan Produksi dsRNA Gonad-Inhibiting Hormone Udang Windu (*Penaeus monodon*) secara In Vitro dan In Vivo pada Vektor Ekspresi L4440. Tesis Program Studi Magister Bioteknologi. Institut Teknologi Bandung.
- [28] Yang F., He J., Lin X., Li Q., Pan D., Zhang X., and Xu X. 2001. Complete Genome Sequence of the Shrimp White Spot Bacilliform Virus. *J Virol*. 75:11811-11820.
- [29] Zhang, X., C. Huang, X. Tang, Y. Zhuang, and C.L. Hew. 2004. Identification of Structural Proteins From Shrimp White Spot Syndrome Virus (WSSV) by 2DE-MS. *Proteins* 55:229-235.

#### AUTHORS

**First Author** – Binayanti, Magister Program of Fisheries

Science, Hasanuddin University

**Second Author** – Hilal Anshary, Marine Science and Fisheries

Faculty of Hasanuddin University

**Third Author** – Andi Parenrengi, Makassar – South Sulawesi

**Fourth Author** – A. Citra Malina, Makassar – South Sulawesi

# Use of dsRNA WSSV VP19 with Different Dose for Infection Control White Spot Syndrome Virus (WSSV) in Vannamee Shrimp.pdf

## ORIGINALITY REPORT

**22%**  
SIMILARITY INDEX

**16%**  
INTERNET SOURCES

**14%**  
PUBLICATIONS

**5%**  
STUDENT PAPERS

## PRIMARY SOURCES

- 1** A Parenrengi, A Tenriulo, S R H Mulyaningrum, E Suryati, R Rosmiati, S Lante, A Nawang. "Effect of different doses of dsRNA VP15 vaccine for controlling white spot syndrome virus infection in tiger shrimp *Penaeus monodon*", IOP Conference Series: Earth and Environmental Science, 2021  
Publication **3%**
- 2** [ejournal-balitbang.kkp.go.id](http://ejournal-balitbang.kkp.go.id)  
Internet Source **2%**
- 3** [orca.cardiff.ac.uk](http://orca.cardiff.ac.uk)  
Internet Source **1%**
- 4** Submitted to University College London  
Student Paper **1%**
- 5** Mohammad Latif Reshi, Jen-Leih Wu, Hao-Ven Wang, Jiann-Ruey Hong. "RNA interference technology used for the study of aquatic virus infections", Fish & Shellfish Immunology, 2014  
Publication **1%**

|    |   |      |
|----|---|------|
| 6  | <a href="http://journalarticle.ukm.my">journalarticle.ukm.my</a><br>Internet Source   | 1 %  |
| 7  | <a href="http://text-id.123dok.com">text-id.123dok.com</a><br>Internet Source   | 1 %  |
| 8  | G. Solís-Lucero, K. Manoutcharian, J. Hernández-López, F. Ascencio. "Injected phage-displayed-VP28 vaccine reduces shrimp <i>Litopenaeus vannamei</i> mortality by white spot syndrome virus infection", <i>Fish &amp; Shellfish Immunology</i> , 2016<br>Publication | 1 %  |
| 9  | <a href="http://repository.unair.ac.id">repository.unair.ac.id</a><br>Internet Source   | 1 %  |
| 10 | <a href="http://eprints.rums.ac.ir">eprints.rums.ac.ir</a><br>Internet Source   | 1 %  |
| 11 | <a href="http://www.biorxiv.org">www.biorxiv.org</a><br>Internet Source   | 1 %  |
| 12 | <a href="http://bora.uib.no">bora.uib.no</a><br>Internet Source   | 1 %  |
| 13 | <a href="http://hdl.handle.net">hdl.handle.net</a><br>Internet Source   | 1 %  |
| 14 | <a href="http://pubmed.ncbi.nlm.nih.gov">pubmed.ncbi.nlm.nih.gov</a><br>Internet Source   | 1 %  |
| 15 | <a href="http://www.thaiscience.info">www.thaiscience.info</a><br>Internet Source   | <1 % |

|    |   |      |
|----|---|------|
| 16 | <a href="https://theses.gla.ac.uk">theses.gla.ac.uk</a><br>Internet Source  | <1 % |
| 17 | <a href="https://science.nature.nps.gov">science.nature.nps.gov</a><br>Internet Source  | <1 % |
| 18 | <a href="https://journal.univetbantara.ac.id">journal.univetbantara.ac.id</a><br>Internet Source  | <1 % |
| 19 | Submitted to University of Newcastle upon Tyne<br>Student Paper   | <1 % |
| 20 | <a href="https://epdf.pub">epdf.pub</a><br>Internet Source  | <1 % |
| 21 | <a href="https://pdfs.semanticscholar.org">pdfs.semanticscholar.org</a><br>Internet Source  | <1 % |
| 22 | L. A. Latifah, N. H. Soekamto, A. Tahir. "NEW ANTIBACTERIAL ACTIVITIES OF BROMINATED C18 AND C20 FATTY ACIDS ISOLATED FROM MARINE SPONGE Xestospongia testudinaria AGAINST SHRIMP PATHOGENIC BACTERIA", Rasayan Journal of Chemistry, 2021<br>Publication | <1 % |
| 23 | <a href="https://docksci.com">docksci.com</a><br>Internet Source  | <1 % |
| 24 | <a href="https://lib.dr.iastate.edu">lib.dr.iastate.edu</a><br>Internet Source  | <1 % |
| 25 | <a href="https://scholarworks.sjsu.edu">scholarworks.sjsu.edu</a><br>Internet Source  | <1 % |

<1 %

26

[www.diagenode.com](http://www.diagenode.com)

Internet Source

<1 %

27

[www.freepatentsonline.com](http://www.freepatentsonline.com)

Internet Source

<1 %

28

Zhu, Y.. "Transcription and identification of a novel envelope protein (VP124) gene of shrimp white spot syndrome virus", *Virus Research*, 200511

Publication

<1 %

29

[amsdottorato.unibo.it](http://amsdottorato.unibo.it)

Internet Source

<1 %

30

"White Spot Syndrome Virus", *Molecular Detection of Animal Viral Pathogens*, 2016.

Publication

<1 %

31

Jade Riet, João Costa-Filho, Laura Dall'Agno, Luiza Medeiros et al. "Bacillus subtilis expressing double-strand RNAs (dsRNAs) induces RNA interference mechanism (RNAi) and increases survival of WSSV-challenged *Litopenaeus vannamei*", *Aquaculture*, 2021

Publication

<1 %

32

Shuying Feng, Chen Wang, Shu Hu, Qiongya Wu, Aifang Li. "Recent progress in the development of white spot syndrome virus

<1 %

# vaccines for protecting shrimp against viral infection", Archives of Virology, 2017

Publication

33

[arccarticles.s3.amazonaws.com](http://arccarticles.s3.amazonaws.com)

Internet Source

<1 %

34

[discovery.ucl.ac.uk](http://discovery.ucl.ac.uk)

Internet Source

<1 %

35

[ediss.uni-goettingen.de](http://ediss.uni-goettingen.de)

Internet Source

<1 %

36

[pt.scribd.com](http://pt.scribd.com)

Internet Source

<1 %

37

[www.researchgate.net](http://www.researchgate.net)

Internet Source

<1 %

38

[www1a.biotech.or.th](http://www1a.biotech.or.th)

Internet Source

<1 %

39

Andi Parenrengi, Alimuddin Alimuddin, Andi Tenriulo. "CHARACTERISTICS OF VIRAL PROTEIN, VP-15, OF WHITESPOT SYNDROME VIRUS ISOLATED FROM INFECTED TIGER SHRIMP *Penaeus monodon* (Fabricius, 1798)", Indonesian Aquaculture Journal, 2017

Publication

<1 %

40

J.-M. Tsai, H.-C. Wang, J.-H. Leu, A. H.-J. Wang, Y. Zhuang, P. J. Walker, G.-H. Kou, C.-F. Lo. "Identification of the Nucleocapsid, Tegument, and Envelope Proteins of the Shrimp White

<1 %

Spot Syndrome Virus Virion", Journal of Virology, 2006

Publication

---

41

Sri Redjeki Hesti Mulyaningrum, Andi Parenrengi, Bunga Rante Tampangallo, Ike Trismawanti. "RESPONS IMUN UDANG WINDU *Penaeus monodon* TERHADAP VAKSIN dsRNA VP-24 PADA DOSIS BERBEDA", Jurnal Riset Akuakultur, 2018

<1 %

Publication

---

Exclude quotes  On

Exclude matches  < 5 words

Exclude bibliography  On